Wan Tai Biology: Application for Clinical Trial of Recombinant Trivalent Rotavirus Subunit Vaccine Accepted.

Wan Tai Biotech announced that the clinical trial application for the "recombinant trivalent rotavirus subunit vaccine" submitted by its wholly-owned subsidiary Xiamen Wan Tai Canghai Biotechnology Co., Ltd. has been accepted by the National Medical Products Administration. This vaccine is used to prevent rotavirus gastroenteritis and was jointly developed by Xiamen University and Xiamen Wan Tai Canghai Biotechnology Co., Ltd. using genetic engineering recombinant technology and E. coli expression system production. As of November 30, 2025, the company has invested approximately 65.8531 million yuan in research and development expenses for this project. The acceptance of this application is an important milestone in the company's innovative vaccine development. If the product is successfully developed and marketed, it will help enrich the company's product portfolio and enhance market competitiveness.